About US
Contact us
-
Sources: Sanofi tells unions a 25% gain at French production sites is neededVery public run-ins between ex-Sanofi CEOChris Viehbacherand France's powerful unions were one factor that reportedly cost him his job. Now his replacement,Olivier Brandicourt, will see if he can do a2015/10/9
-
Merck notches another win in India patent battle over diabetes bestsellersEverything is coming up roses for Merck ($MRK) in its patent battle withIndia'sGlenmark Pharmaceuticalsover copycats of the drugmaker's diabetes medsJanuviaandJanumet, as the Delhi High Court barred t2015/10/8
-
Sanofi offers some data that might help Aubagio as it chases market shareSanofi'smultiple sclerosispillAubagiohas been an also-ran behind established drugs like Teva's ($TEVA)Copaxoneand newer drugs like Biogen's ($BIIB)Tecfidera. But the French drugmaker has not given up2015/10/8
-
Pfizer CEO sees no real future for Clinton's drug-pricing proposalsPfizer ($PFE) CEOIan Readisn't too worried about proposals to crack down on U.S. drug pricing. Presidential candidateHillary Clinton's slate of new measures--which include negotiating power for Medica2015/9/30
-
Who's most at risk if the U.S. cracks down on prices? Gilead, Celgene top the listWith pharma's U.S. pricing power apparently in jeopardy, industry watchers are worried. Just take a look at drug stocks' performance over the past week or so, as a firestorm over an enormous price inc2015/9/30
-
Don't count Merck's Keytruda out in lung cancer fight with BMS' OpdivoThose following the checkpoint inhibitor battle between Bristol-Myers Squibb's ($BMY)Opdivoand Merck's ($MRK)Keytruda--particularly in the lung cancer arena--know that industry watchers largely expect2015/9/29
-
Sanofi patent deal lets Lilly roll out a Lantus biosim in U.S. next DecemberSettlement covers SoloSTAR pen version, with more than 60% of franchise sales Sanofi has put off one biosimilar threat to Lantus till the end of 2016. In a patent settlement announced on Monday, the2015/9/29
-
Roche is 'well placed' for U.S. pricing tussle, CEO saysWorried about how mounting pricing pushback will affect Roche ($RHHBY)? Don't be, CEO Severin Schwan told Swiss newspaperFinanz und Wirtschaft. "Pressure will rise on drugs that are less sophisticated2015/9/28
-
Novartis scores EU rec for blockbuster-to-be EntrestoNovartis ($NVS) has predicted that its launch of newlyFDA-approved heart failure medEntrestowould be its "most exciting" ever. And now, it's one step closer to bringing that excitement to Europe. The2015/9/28
-
BMJ points up 'wide variations' in quality of data for new FDA indicationsOne of pharma's key strategies for growing a drug's sales is expanding into bigger groups of patients. Sometimes new meds hit the market for small-scale--even rare--diseases and then win approval for2015/9/25